Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11851.145 | 1.0009 | 1.0012 | 1.4873 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 11851.145 | 0.9054 | 0.8708 | 1.4873 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 11851.145 | 0.9384 | 0.9163 | 1.4873 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 11851.145 | 0.9172 | 0.8871 | 1.4873 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 11851.145 | 1.0626 | 1.0833 | 1.4873 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 11851.145 | 1.0878 | 1.1165 | 1.4873 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 10875.145 | 0.9933 | 0.9824 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 10875.145 | 1.0096 | 1.0251 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 10875.145 | 1.0480 | 1.1264 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 10875.145 | 1.0608 | 1.1605 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 10875.145 | 1.1219 | 1.3249 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 10875.145 | 1.1708 | 1.4583 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 10875.145 | 1.1093 | 1.2907 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 10875.145 | 1.1508 | 1.4035 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 10875.145 | 1.1744 | 1.4681 | 0.7643 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12428.17 | 0.9852 | 0.9696 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12428.17 | 1.0327 | 1.0674 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12428.17 | 1.0393 | 1.0810 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12428.17 | 1.1239 | 1.2553 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12428.17 | 1.1189 | 1.2450 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12428.17 | 1.2122 | 1.4376 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12428.17 | 1.0937 | 1.1929 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12428.17 | 1.2081 | 1.4292 | 0.9724 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12428.17 | 1.1933 | 1.3987 | 0.9724 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 10819.145 | 1.0078 | 1.0071 | 2.1971 |